Head-To-Head Contrast: BioScrip (BIOS) versus Its Rivals
BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it weigh in compared to its competitors? We will compare BioScrip to similar businesses based on the strength of its institutional ownership, dividends, analyst recommendations, valuation, risk, profitability and earnings.
This table compares BioScrip and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BioScrip and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-3.99|
|BioScrip Competitors||$1.06 billion||-$22.56 million||770.38|
BioScrip’s competitors have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
BioScrip has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s competitors have a beta of 0.87, suggesting that their average stock price is 13% less volatile than the S&P 500.
This is a breakdown of recent recommendations for BioScrip and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip presently has a consensus target price of $3.75, suggesting a potential upside of 38.38%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 18.55%. Given BioScrip’s stronger consensus rating and higher possible upside, analysts plainly believe BioScrip is more favorable than its competitors.
Insider and Institutional Ownership
84.7% of BioScrip shares are held by institutional investors. Comparatively, 69.6% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by institutional investors. 0.8% of BioScrip shares are held by insiders. Comparatively, 10.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BioScrip competitors beat BioScrip on 8 of the 12 factors compared.
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.